Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 13 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.05 Insider Own3.93% Shs Outstand71.75M Perf Week-11.61%
Market Cap169.33M Forward P/E- EPS next Y-0.66 Insider Trans0.00% Shs Float68.93M Perf Month-22.37%
Income-65.35M PEG- EPS next Q-0.29 Inst Own13.77% Short Float0.62% Perf Quarter-6.72%
Sales5.14M P/S32.94 EPS this Y58.94% Inst Trans-2.50% Short Ratio8.77 Perf Half Y-18.62%
Book/sh1.26 P/B1.88 EPS next Y8.82% ROA-25.90% Short Interest0.42M Perf Year18.00%
Cash/sh2.97 P/C0.79 EPS next 5Y- ROE-76.82% 52W Range0.96 - 3.77 Perf YTD-23.38%
Dividend Est.- P/FCF- EPS past 5Y1.69% ROI-36.07% 52W High-37.46% Beta3.13
Dividend TTM- Quick Ratio1.63 Sales past 5Y42.86% Gross Margin-269.58% 52W Low145.12% ATR (14)0.15
Dividend Ex-Date- Current Ratio1.63 EPS Y/Y TTM53.69% Oper. Margin-2023.96% RSI (14)30.57 Volatility4.46% 4.62%
Employees221 Debt/Eq1.15 Sales Y/Y TTM-70.98% Profit Margin-1270.39% Recom1.50 Target Price7.00
Option/ShortYes / Yes LT Debt/Eq1.00 EPS Q/Q109.36% Payout- Rel Volume0.00 Prev Close2.36
Sales Surprise75.75% EPS Surprise124.24% Sales Q/Q3157.55% EarningsMay 28 AMC Avg Volume48.36K Price2.36
SMA20-13.45% SMA50-14.23% SMA200-6.35% Trades Volume0 Change0.00%
Date Action Analyst Rating Change Price Target Change
Mar-17-23Initiated Bryan Garnier Buy $6
May-18-22Upgrade Robert W. Baird Neutral → Outperform $10
Jan-06-22Downgrade Wells Fargo Overweight → Equal Weight $39 → $16
Nov-30-21Initiated JMP Securities Mkt Outperform $20
Nov-08-21Downgrade William Blair Outperform → Mkt Perform
Oct-08-21Downgrade Robert W. Baird Outperform → Neutral $39 → $10
Apr-28-21Downgrade Guggenheim Buy → Neutral
Mar-16-21Upgrade Robert W. Baird Neutral → Outperform $23 → $39
Aug-19-20Upgrade Citigroup Neutral → Buy $15 → $32
May-12-20Initiated Robert W. Baird Outperform $20
Jun-12-24 04:30PM
Jun-05-24 04:30PM
Jun-04-24 04:30PM
May-29-24 04:30PM
May-28-24 08:52PM
04:30PM Loading…
May-27-24 04:30PM
May-16-24 04:30PM
May-06-24 04:30PM
May-03-24 06:10AM
May-02-24 04:30PM
Apr-29-24 10:53PM
04:30PM Loading…
Apr-22-24 04:30PM
Apr-10-24 04:30PM
Apr-08-24 04:30PM
Apr-04-24 04:30PM
Mar-04-24 04:30PM
Feb-02-24 04:30PM
Jan-16-24 04:30PM
Jan-08-24 04:30PM
Dec-22-23 04:30PM
Dec-01-23 04:30PM
Nov-17-23 04:30PM
Nov-15-23 02:30AM
Nov-06-23 04:30PM
Nov-03-23 04:30PM
Nov-02-23 04:30PM
04:30PM Loading…
Nov-01-23 04:30PM
Oct-31-23 04:30PM
Oct-24-23 04:30PM
Oct-12-23 04:30PM
Oct-03-23 04:30PM
Sep-27-23 04:30PM
Sep-05-23 04:30PM
Aug-07-23 04:30PM
Aug-03-23 04:30PM
Aug-01-23 04:30PM
Jul-27-23 04:30PM
Jul-12-23 04:30PM
Jun-28-23 04:30PM
Jun-13-23 04:30PM
Jun-09-23 04:30PM
Jun-05-23 04:30PM
May-31-23 04:50PM
May-17-23 04:30PM
May-12-23 01:30AM
May-11-23 10:20AM
May-10-23 04:30PM
May-04-23 04:30PM
May-02-23 04:35PM
Apr-27-23 04:30PM
Apr-24-23 04:30PM
Apr-17-23 02:00AM
Apr-12-23 04:30PM
Apr-11-23 04:30PM
Apr-04-23 04:30PM
Mar-15-23 05:02PM
Mar-14-23 05:00PM
Mar-08-23 04:45PM
Mar-06-23 04:30PM
Mar-01-23 04:30PM
Feb-09-23 04:30PM
Feb-07-23 07:01PM
Feb-03-23 09:33AM
Feb-02-23 04:01PM
Jan-30-23 07:10PM
Jan-20-23 04:30PM
Jan-17-23 07:10AM
Jan-09-23 04:30PM
Jan-04-23 05:08PM
Dec-29-22 04:30PM
Dec-28-22 04:30PM
Dec-22-22 04:30PM
Dec-16-22 04:30PM
Dec-13-22 01:47PM
Dec-01-22 04:40PM
Nov-10-22 09:05AM
Nov-08-22 04:30PM
Nov-04-22 12:31PM
Nov-03-22 04:36PM
Oct-27-22 04:37PM
Oct-11-22 04:30PM
Oct-10-22 04:30PM
Oct-05-22 09:45AM
Sep-28-22 04:23PM
Sep-19-22 04:30PM
Sep-01-22 04:44PM
Aug-22-22 04:30PM
Aug-05-22 12:13PM
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and Andre Choulika on February 20, 1999 and is headquartered in Paris, France.